Northfield Lab(NFLD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Northfield Lab(NFLD)

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: BKS who wrote ()	4/28/1996 9:58:00 PM
From: olduser	of 148

BKS: This company makes a blood substitue called Polyheme which is derived form banked hemoglobin which has expired on the shelf. NFLD seems to have perfected the process of extracting the hemoglobin (which is the oxygen carrying molecule in blood) while discarding the rest of the cellular elements in blood. The product is therefore pure and free of infectious potential. NFLD is currently in late phase II clinical trials, i.e it is testing the product on patients in a controlled many in a multi-center trial setting. Preliminary results from ealiar trials were extremely encouraging. To date no other company is as far along in bringing a blood substitute to market. The upside potential for the stock is astronomical were the trial results as expected and FDA approval forthcoming. If not then....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext